Synthorx Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Synthorx's estimated annual revenue is currently $3.3M per year.(i)
  • Synthorx received $63.0M in venture funding in May 2018.
  • Synthorx's estimated revenue per employee is $162,750
  • Synthorx's total funding is $76.1M.

Employee Data

  • Synthorx has 20 Employees.(i)
  • Synthorx grew their employee count by -29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx's expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded based on important discoveries in Dr. Floyd Romesberg's lab at The Scripps Research Institute in conjunction with Avalon Ventures, which housed Synthorx in its incubator, COI Pharmaceuticals, Inc. The company is headquartered in La Jolla, Calif.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Synthorx News

2022-03-30 - Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application, By Type, By Regional Outlook and Forecast, 2021 - 2027

Jan-2020: Sanofi completed the acquisition of Synthorx, a clinical-stage biotechnology company. Through this collaboration, Sanofi aimed to...

2019-09-03 - Synthorx to Present at HC Wainwright 21st Annual Global ...

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (THOR), a clinical-stage biotechnology company developing optimized ...

2019-09-03 - Synthorx (NASDAQ:THOR) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of Synthorx (NASDAQ:THOR) from a hold rating to a buy rating in a research report sent to investors on Thursday, ...

2019-08-12 - Scripps bigshot who cofounded Synthorx exits amid mystery

Floyd Romesberg, Ph.D., the renowned Scripps Research scientist and scientific founder of synthetic cytokine biotech Synthorx, has bid the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Synthorx Funding

DateAmountRoundLead InvestorsReference
2014-05-09$UndisclosedUndisclosedAvalon VenturesArticle
2016-07-20$10.0MBRA Capital ManagementArticle